First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

First (18)F-labeled ligand for PET imaging of uPAR : In vivo studies in human prostate cancer xenografts. / Persson, Morten; Liu, Hongguang; Madsen, Jacob; Cheng, Zhen; Kjaer, Andreas.

In: Nuclear Medicine and Biology, Vol. 40, No. 5, 07.2013, p. 618-24.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Persson, M, Liu, H, Madsen, J, Cheng, Z & Kjaer, A 2013, 'First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts', Nuclear Medicine and Biology, vol. 40, no. 5, pp. 618-24. https://doi.org/10.1016/j.nucmedbio.2013.03.001

APA

Persson, M., Liu, H., Madsen, J., Cheng, Z., & Kjaer, A. (2013). First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts. Nuclear Medicine and Biology, 40(5), 618-24. https://doi.org/10.1016/j.nucmedbio.2013.03.001

Vancouver

Persson M, Liu H, Madsen J, Cheng Z, Kjaer A. First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts. Nuclear Medicine and Biology. 2013 Jul;40(5):618-24. https://doi.org/10.1016/j.nucmedbio.2013.03.001

Author

Persson, Morten ; Liu, Hongguang ; Madsen, Jacob ; Cheng, Zhen ; Kjaer, Andreas. / First (18)F-labeled ligand for PET imaging of uPAR : In vivo studies in human prostate cancer xenografts. In: Nuclear Medicine and Biology. 2013 ; Vol. 40, No. 5. pp. 618-24.

Bibtex

@article{42ca3a9a315c4da99299c9799a8669ca,
title = "First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts",
abstract = "Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.",
author = "Morten Persson and Hongguang Liu and Jacob Madsen and Zhen Cheng and Andreas Kjaer",
note = "Copyright {\textcopyright} 2013 Elsevier Inc. All rights reserved.",
year = "2013",
month = jul,
doi = "10.1016/j.nucmedbio.2013.03.001",
language = "English",
volume = "40",
pages = "618--24",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - First (18)F-labeled ligand for PET imaging of uPAR

T2 - In vivo studies in human prostate cancer xenografts

AU - Persson, Morten

AU - Liu, Hongguang

AU - Madsen, Jacob

AU - Cheng, Zhen

AU - Kjaer, Andreas

N1 - Copyright © 2013 Elsevier Inc. All rights reserved.

PY - 2013/7

Y1 - 2013/7

N2 - Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.

AB - Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.

U2 - 10.1016/j.nucmedbio.2013.03.001

DO - 10.1016/j.nucmedbio.2013.03.001

M3 - Journal article

C2 - 23602763

VL - 40

SP - 618

EP - 624

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 5

ER -

ID: 45945354